Market capitalization | $6.94m |
Enterprise Value | $2.32m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.07 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-8.31m |
Free Cash Flow (TTM) Free Cash Flow | $-12.17m |
Cash position | $4.75m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
2 Analysts have issued a Vallon Pharmaceuticals Inc forecast:
2 Analysts have issued a Vallon Pharmaceuticals Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.02 -0.02 |
-
|
|
EBITDA | -8.29 -8.29 |
31%
31%
|
EBIT (Operating Income) EBIT | -8.31 -8.31 |
31%
31%
|
Net Profit | -8.26 -8.26 |
36%
36%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Vallon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of proprietary biopharmaceutical products. The firm's primary product is Abuse-Deterrent Amphetamine Immediate and its product pipeline includes ADAIR, ADMIR, ADHD, and Narcolepsy. The company was founded by David C. Baker on January 11, 2018 and is headquartered in Philadelphia, PA.
Head office | United States |
CEO | W. Hertz |
Employees | 4 |
Founded | 2009 |
Website | www.gribio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.